Zusammenfassung
Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Medikamente gegen Schlafstörungen beschrieben. Diese werden entsprechend den DSM-5-Kriterien neu geordnet. Die Strukturen innerhalb der einzelnen Diagnosen sind geblieben.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Allen RP, Picchietti DL, Auerbach M et al (2018) International Restless Legs Syndrome Study Group (IRLSSG). Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med 41: 27–44
Dresler M, Spoormaker VI, Beitinger P et al (2014) Neuroscience-driven discovery and development of sleep therapeutics. Pharmacol Ther 141: 300–334
Garcia-Borreguero D, Cano-Pumarega I (2017) New concepts in the management of restless legs syndrome. BMJ 356: j104
Iftikhar IH, Alghothani L, Trotti LM (2017) Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis. Eur J Neurol 24(12): 1446–1456
Keks NA, Hope J, Keogh S (2017) Suvorexant: scientifically interesting, utility uncertain. Australasian Psychiatry 25: 622–624
Mayer G (2014) Narkolepsie. Nervenarzt 85: 26–34
Moore TJ, Glemullen J, Mattison DR (2014) Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 174(12): 1930–1933
Muehlan C, Heuberger J, Juif PE et al (2018) Accelerated development of the dual orexin receptor antagonist ACT-541468: integration of a microtracer in a first-in-human study. Clin Pharmacol Ther. doi:10.1002/cpt.1046 [Epub ahead of print]
Nissen C, Frase L, Hajak G, Wetter TC (2014) Hypnotika – Stand der Forschung. Nervenarzt 85: 67–76
Pollmächer T, Wetter TC, Happe S et al (2014) Schlafmedizinische Differenzialdiagnostik in Psychiatrie und Psychotherapie. Nervenarzt 85: 57–66
Riemann D, Baglioni C, Feige B, Spiegelhalder K (2014) Insomnien – Stand der Forschung. Nervenarzt 85: 43–49
Riemann D, Baglioni C, Basetti C et al (2017a) European guideline for the diagnosis and treatment of insomnia. J Sleep Res 26: 675–600
Riemann D, Baum E, Cohrs S et al (2017b) S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen. Kapitel „Isomnie bei Erwachsenen“. Somnologie 21: 2–44
Saper CB, Fuller PM (2017) Wake-sleep circuitry: an overview. Curr Opin Neurobiol 44: 186–192
Silber MH, Becker PM, Buchfuhrer MJ et al; Scientific and Medical Advisory Board, Restless Legs Syndrome Foundation (2018) The appropriate use of opioids in the treatment of refractory restless legs syndrome. Mayo Clin Proc 93(1): 59–67
Steiger A, Pawlowski M, Kimura M (2015) Sleep electroencephalography as a biomarker in depression. ChronoPhysiol Ther 5: 15–25
Trenkwalder C, Benes H, Grote L et al, for the RELOXYN Study Group (2013) Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol 12: 1141–1150
Trenkwalder C, Winkelmann J, Inoue Y, Paulus W (2015) Restless legs syndrome – current therapies and management of augmentation. Nat Rev Neurol 11(8): 434–445
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer-Verlag GmbH Deutschland
About this chapter
Cite this chapter
Steiger, A., Weber, F., Benkert, O. (2019). Medikamente zur Behandlung von Schlafstörungen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57334-1_5
Download citation
DOI: https://doi.org/10.1007/978-3-662-57334-1_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57333-4
Online ISBN: 978-3-662-57334-1
eBook Packages: Medicine (German Language)